Gilead­'s Kite dou­bles down on Ar­cel­lx's blood can­cer cell ther­a­pies with $285M

Gilead’s cell ther­a­py unit Kite wants more of what it ini­tial­ly got from Ar­cel­lx last De­cem­ber, buy­ing $200 mil­lion worth of eq­ui­ty in Ar­cel­lx and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA